207_Combined course Presentations

CMS4 stemlike

Del Rio M, et al. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017 May;76:68-75 87% response to FOLFIRI in CMS4 Song N, et al. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol. 2016 Sep 1;2(9):1162-9 Lack of benefit from Oxaliplatin/poor prognosis in CMS4